Castle Biosciences, Inc. Common Stock
$36.52
$1.04 (+2.93%)
$34.94Day Range$36.74
Key Statistics
Market Cap
$1.08B
Shares Outstanding
30.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 25, 2019
Round Lot
100
Locale
US
Trading Data
Day Open
$35.98
Day High
$36.74
Day Low
$34.94
Volume
176.2K
VWAP
$36.27
Prev Close
$35.48
Transactions
--
Acc. Volume
--
About Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
SERVICES-MEDICAL LABORATORIESSIC 80711,002 employees1500 W. PARKWOOD AVE., FRIENDSWOOD, TX, 77546866-788-9007IPO Jul 25, 2019US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001447362
- Composite FIGI
- BBG006YWVSR3
- Share Class FIGI
- BBG006YWVSS2
- Ticker Root
- CSTL
- SIC Code
- 8071
About Castle Biosciences, Inc. Common Stock (CSTL) Stock
Castle Biosciences, Inc. Common Stock (CSTL) closed the 2026-09-17 session at $36.52, up 2.93% versus the previous close (+1.04). The stock opened at $35.98 and traded between $34.94 and $36.74 during that session. Session trading volume was 176K shares. The volume-weighted average price (VWAP) is $36.27.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Castle Biosciences, Inc. Common Stock has a market capitalization of $1.08 billion. The company operates in the SERVICES-MEDICAL LABORATORIES industry classification. CSTL is listed on the XNAS exchange. The company employs approximately 1,002 people. Castle Biosciences, Inc. Common Stock is headquartered in FRIENDSWOOD, TX. The recorded listing date is 2019-07-25.
On this page you can find market CSTL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the SERVICES-MEDICAL LABORATORIES sector.